This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity.
The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The company is currently developing an antibody that might reliably protect the head’s hair follicles from chemotherapy damage — if it works. But, to her, it wasn’t much of an option.
MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments. The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years.
After finding a “cascade of failures” at a manufacturing plant run by a key chemotherapy supplier, the Food and Drug Administration will not allow the company to resume distribution in the U.S. beyond some cancer medicines that are in short supply.
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday. The standard treatment after surgery for these patients is chemotherapy.
The Phase 3 trial tested the PD-1 targeting antibody retifanlimab in combination with chemotherapy versus chemotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the anal canal. In the study, adding retifanlimab to chemotherapy cut the risk of disease progression or death by more than a third.
Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed. Continue to STAT+ to read the full story…
But she avoided digging into one particular subject: what she might have to endure with chemotherapy and radiation. When Rachel Guberman found out she had brain cancer, she did so much reading and Googling about the disease that she joked she had reached the end of the internet. Continue to STAT+ to read the full story…
A clinical trial in malignant pleural mesothelioma (MPM) has demonstrated the first successful combination of chemotherapy with a drug targeting cancer’s metabolism developed for the asbestos-induced disease in two decades. The anti-cancer treatment combines the new drug ADI-PEG20 and traditional chemotherapy.
The drug has been approved in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 […] The post FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment appeared (..)
The blood-brain barrier (BBB) in glioblastoma patients was opened temporarily using a novel, skull-implantable ultrasound device to deliver chemotherapy to the brain in a first in-human trial. Two chemotherapy drugs , paclitaxel and carboplatin were injected intravenously during the four-minute procedure.
A year after an investigation revealed widespread use of a substandard cancer drug, the World Health Organization and national drug regulators around the world have come under fire for failing to protect children from the dangerous chemotherapy. The WHO plays a major role in protecting people worldwide from bad medicines.
Like the two sickle cell gene therapies approved last year, Editas’ old program, Reni-Cel, required extracting a patient’s blood cells, editing them at a large facility, and then reinfusing — an expensive and difficult-to-scale process that requires patients to undergo intensive chemotherapy.
Venus Remedies has received marketing approval from the Philippines, the second largest ASEAN market, for six key chemotherapy drugs. Meanwhile, the company’s oncology wing has also secured marketing approval from Myanmar for the chemotherapy drug oxaliplatin.
Many will endure multiple CT and MRI studies and intensive medical care, including surgery, radiation, chemotherapy, or immunotherapy. In 2023, just under 2 million Americans will be diagnosed with cancer. Fortunately, advances in treatment and novel therapies have steadily improved survival following a cancer diagnosis.
CHICAGO — An antibody that delivers chemotherapy directly to tumor cells extended the lives of women with a form of advanced ovarian cancer in a large study, researchers reported Sunday. months compared to just under 13 months for participants treated with standard chemotherapy. It was granted conditional approval in the U.S.
The charges are actually eating into their financial well-being, particularly for people who have cancer and have to make frequent visits to the hospital for treatments like radiation and chemotherapy. Read the rest…
months for comparator chemotherapy. In the study, called TROPICS-02, Trodelvy showed a median overall survival of 14.4 months compared to 11.2 The survival benefit of 3.2 months was statistically significant and translated into a 21% reduction in the risk of death. Continue to STAT+ to read the full story…
Susan underwent two lumpectomies, a mastectomy, radiation, and chemotherapy. She embarked on a challenging path of treatment, including a recurrence with stage 2 cancer four years later.
BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and chemotherapy improved responses for certain patients with a type of lung cancer, steering the approach into a Phase 3 study.
For months, oncologist Kristen Rice found herself scrambling for cisplatin and carboplatin, two key chemotherapies used for many different cancers including ovarian, bladder, and lung cancer. We went to put in our chemotherapy order, and our supplier said, ‘We don’t have any.’ “It came without warning.
These include oxytocin, which is used during childbirth; Rho(D) immune globulin, which helps some women during pregnancy; standard-of-care chemotherapy, pain and sedation medicines; and ADHD pills. Unresolved shortages have, in fact, been hovering above 300 for more than a year as numerous basic and life-saving medicines are in short supply.
Immunogen released data from a trial comparing the new drug, Elahere, to traditional chemotherapy in 453 ovarian cancer patients who had already progressed on at least one other therapy and had a particular protein marker on their tumor. months for patients on chemotherapy. Patients who received Elahere lived a median of 16.46
Diagnosed at age 3 with acute myeloid leukemia, an aggressive blood cancer, Logan happened to have a targetable mutation that occurs in a small minority of childhood AML cases, making it possible for him to receive a precision therapy drug that — with chemotherapy — got him to a point where he could receive a bone marrow transplant.
When Jeannette Cleland learned earlier this year that she could get chemotherapy at home, after dropping a particularly toxic medication, it seemed like good news. But then Cleland, a 44-year-old Minneapolis event planner who has stage 4 pancreatic cancer, did the math. Read the rest…
The latest entry is that of Catherine, the Princess of Wales, also known as Kate Middleton, who revealed she has cancer and is undergoing chemotherapy. As with her many of her predecessors, the princess’s story will likely both reveal and conceal, but I suspect it will ultimately both move and enlighten the public.
The move comes amid growing anxiety over shortages of numerous medicines — from chemotherapies to antibiotics — in recent years. Three group purchasing organizations, or GPOs, buy drugs on behalf of most hospitals in the U.S.,
A non-chemotherapy multi-drug therapy enabled complete remission in 38 percent of evaluable patients with aggressive B-cell lymphoma, a Phase Ib/II clinical trial shows. The post Non-chemotherapy lymphoma treatment may provide durable remission appeared first on European Pharmaceutical Review.
While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.
Despite treatments such as surgery, radiation therapy and chemotherapy, only about a quarter of all people with the disease will live more than five years after diagnosis, and lung cancer kills more than 1.8 Lung cancer is not the most common form of cancer, but it is by far the deadliest.
Results presented from the Phase III IMpower133 study and extension trial IMbrella A, show Roche’s Tecentriq (atezolizumab), in combination with chemotherapy, demonstrates a potential long-term overall survival (OS) benefit as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). 0.91; p=0.0069). JTO Clin Res Rep.
The medicine, datopotamab deruxtecan, or Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies have been pouring investments into. But full trial data published in September showed Dato-DXd did not outperform standard chemotherapy on overall survival.
The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.
Elahere is among a surging class of cancer medicines called antibody-drug conjugates , or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues.
For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and targeted drugs have joined or replaced older, blunter tools like chemotherapy and radiation. Children have been less fortunate.
Cancer patients, like those I treat in San Diego and thousands more across the country, are facing an alarming shortage of critical chemotherapy drugs, forcing oncologists to ration cancer treatment doses for patients with curable diseases.
The other scenario involved treatments that were more expensive, but no more effective than alternatives, such as the Abraxane chemotherapy. Overall, the proportion of patients who were prescribed so-called low-value drugs was higher when their oncologist accepted industry payments, according to the study, published in the BMJ.
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. But some in the industry worry about the unintended consequences of overreliance.
Like many cancer patients, Sarah’s treatment at Dana-Farber was co-managed by its longtime medical partner, Brigham and Women’s Hospital: Her three surgeries were performed at the Brigham, by Brigham doctors; her five rounds of chemotherapy at Dana-Farber. Continue to STAT+ to read the full story…
The trial met its primary endpoint of investigator-assessed progression-free survival (PFS), showing a statistically significant and clinically meaningful benefit versus placebo plus chemotherapy in patients treated with dostarlimab plus carboplatin-paclitaxel in the dMMR/MSI-H population.
Among this vulnerable group are people with cancer undergoing chemotherapy, recipients of organ transplants, those with autoimmune conditions, and others.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content